The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.

BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced successful completion of an $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital.

NEW YORK, Dec. 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, BITF, NIO, LI, and MIRA.

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, AMZN, LI, LAC, and GM.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.